Skip to content

Released Nov 14, 2024, after the close

10-Q filed Nov 14, 2024, 45 days after period end · 0000950170-24-127016

Q3 2024 · 10-Q
Revenue$65.00K−70.2% vs Q3 2023−43.0% vs Q2 2024
Net Income-$17.15MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.32N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$18,593,000N/M
Operating Cash Flowderived$12,763,000−19.8%
Margins · derived
Operating margin-28604.6%−27717.5 pt vs Q3 2023
Net margin-26380.0%−24912.1 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$65.00K$218.00K$1.08M$708.00K
Net Income-$17.15M-$3.20M-$11.70M-$22.50M
EPS Diluted-$0.32-$0.06-$0.33-$0.70

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR